Lee P-C, Ozawa M, Hung C-J, Lin Y-J, Chang S-S, Chou T-C
Medical College, National Cheng Kung University, Tainan, Taiwan.
Transplant Proc. 2009 Jan-Feb;41(1):95-8. doi: 10.1016/j.transproceed.2008.10.074.
Enzyme-linked immunosorbent assay (ELISA) and flow cytometric techniques have been introduced to overcome the limited sensitivity and specificity of the CDC assay. This retrospective study used lambda antigen tray-mixed screening and Luminex HLA class I and II specificity assays to re-examine: (1) the accuracy with which detection of HLA antibody and specificity by ELISA predicts pretransplantation National Institutes of Health (NIH)/Centers for Disease Control and Prevention (CDC) crossmatch; and (2) a comparison of Luminex and ELISA methods to detect HLA antibodies. Sera from 481 patients awaiting kidney transplantation were tested using the ELISA method lambda antigen tray-mixed and using NIH-CDC to determine how well HLA antibodies detected using ELISA predicted crossmatches using CDC. Pretransplantation sera from 48 patients with follow-up data were retested using both ELISA lambda antigen tray-mixed and Luminex to compare the efficacy of the 2 methods.
酶联免疫吸附测定（ELISA）和流式细胞术已被引入，以克服疾病控制与预防中心（CDC）检测方法灵敏度和特异性有限的问题。这项回顾性研究采用λ抗原板混合筛查以及Luminex HLA I类和II类特异性检测方法，重新检验：（1）通过ELISA检测HLA抗体及其特异性预测移植前美国国立卫生研究院（NIH）/疾病控制与预防中心（CDC）交叉配型的准确性；（2）比较Luminex和ELISA方法检测HLA抗体的效果。使用ELISA方法的λ抗原板混合检测法对481例等待肾移植患者的血清进行检测，并使用NIH-CDC方法来确定ELISA检测出的HLA抗体预测CDC交叉配型的效果如何。对48例有随访数据的移植前患者血清，同时使用ELISA λ抗原板混合检测法和Luminex进行重新检测，以比较这两种方法的效果。
